Abstract
Cancer vaccines have garnered great interest as a potential arsenal to treat patients with cancer. The main goal and challenge in cancer immunotherapy includes the activation of the otherwise indolent immune system of cancer patients. It has been discovered that cytotoxic T cell mediated immune response is most efficacious in killing cancer cells. However, even if the immune system of a cancer patient is activated, there is no guarantee that such activation will be translated into cancer cell death. Nanotechnology has already transformed the field of small molecule therapy and holds promise to have similar impact on the field of cancer vaccines. Nanoparticles can be tailored to target specific receptors in immune competent or cancer cells and even elicit specific type of immune response. Desirable effects of nanoparticles can be controlled through modification of factors such shape, size, surface charge, composition, and hydrophobicity. Another advantage of nanoparticles includes the ability of simultaneous delivery of multiple antigens and adjuvant-antigen combinations, thereby increasing the likelihood of triggering an immune response. Extrapolating from the progress that nanoparticles have helped to make in other areas, it can be anticipated that nanotechnology approach would accelerate the process of clinical applications of cancer vaccines.
Keywords: Adjuvants, antigens, cancer, liposomes, nanoparticles, polymers, therapeutic vaccines, virus-like particles.
Graphical Abstract
Pharmaceutical Nanotechnology
Title:Nanoparticles in the Development of Therapeutic Cancer Vaccines
Volume: 2 Issue: 1
Author(s): Ronak Savla, Vera Ivanova and Tamara Minko
Affiliation:
Keywords: Adjuvants, antigens, cancer, liposomes, nanoparticles, polymers, therapeutic vaccines, virus-like particles.
Abstract: Cancer vaccines have garnered great interest as a potential arsenal to treat patients with cancer. The main goal and challenge in cancer immunotherapy includes the activation of the otherwise indolent immune system of cancer patients. It has been discovered that cytotoxic T cell mediated immune response is most efficacious in killing cancer cells. However, even if the immune system of a cancer patient is activated, there is no guarantee that such activation will be translated into cancer cell death. Nanotechnology has already transformed the field of small molecule therapy and holds promise to have similar impact on the field of cancer vaccines. Nanoparticles can be tailored to target specific receptors in immune competent or cancer cells and even elicit specific type of immune response. Desirable effects of nanoparticles can be controlled through modification of factors such shape, size, surface charge, composition, and hydrophobicity. Another advantage of nanoparticles includes the ability of simultaneous delivery of multiple antigens and adjuvant-antigen combinations, thereby increasing the likelihood of triggering an immune response. Extrapolating from the progress that nanoparticles have helped to make in other areas, it can be anticipated that nanotechnology approach would accelerate the process of clinical applications of cancer vaccines.
Export Options
About this article
Cite this article as:
Savla Ronak, Ivanova Vera and Minko Tamara, Nanoparticles in the Development of Therapeutic Cancer Vaccines, Pharmaceutical Nanotechnology 2014; 2 (1) . https://dx.doi.org/10.2174/2211738502666140220004628
DOI https://dx.doi.org/10.2174/2211738502666140220004628 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Binary Organic Solvents Together with Emulsifier on Particle Size and In vitro Behavior of Paclitaxel-Encapsulated Polymeric Lipid Nanoparticles
Current Drug Delivery Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Steroids and the Endometrium
Current Medicinal Chemistry Sentinel Lymph Node Identification in Patients with Stage IB1 Invasive Cervical Carcinoma
Current Cancer Therapy Reviews GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design CYP17 Inhibitors for Prostate Cancer Treatment – An Update
Current Medicinal Chemistry Role of Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Basic Aspects, Clinical Applications, and Future Prospects
Current Cancer Drug Targets Advanced Cardiac Imaging of Radiation-induced Injury - a Review
Current Medical Imaging Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Nucleic Acid Aptamers Against Proteases
Current Medicinal Chemistry Comparative Study of Aromatase Enzyme Inhibition by Synthetic and Natural Ligand: Molecular Modeling and Conceptual DFT Investigation
Current Enzyme Inhibition Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets Designing and Testing New Therapeutic Modalities for Treatment of Inflammatory Bowel Disease: Role of Experimental Animal Models
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity
Current Topics in Medicinal Chemistry Recent Advances in Liposome Techniques and their Applications in Arthritis
Recent Patents on Biomedical Engineering (Discontinued) Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells
Medicinal Chemistry The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Plant Spliceosomal Introns: Not Only Cut and Paste
Current Genomics